Article Text

other Versions

PDF
Effectiveness and safety of tocilizumab therapy for patients with rheumatoid arthritis and renal insufficiency: a real-life registry study in Japan (the ACTRA-RI study)
  1. Shunsuke Mori1,
  2. Tamami Yoshitama2,
  3. Toshihiko Hidaka3,
  4. Naoyuki Hirakata4,
  5. Yukitaka Ueki4
  1. 1Department of Rheumatology, Clinical Research Center for Rheumatic Diseases, NHO Kumamoto Saishunsou National Hospital, Kohshi, Kumamoto, Japan
  2. 2Yoshitama Clinic for Rheumatic Diseases, Kirishima, Kagoshima, Japan
  3. 3Institute of Rheumatology, Zenjinkai Shimin-no-Mori Hospital, Miyazaki, Japan
  4. 4Rheumatic and Collagen Disease Center, Sasebo Chuo Hospital, Sasebo, Nagasaki, Japan
  1. Correspondence to Dr Shunsuke Mori, Department of Rheumatology, Clinical Research Center for Rheumatic Diseases, NHO Kumamoto Saishunsou National Hospital, 2659 Suya, Kohshi, Kumamoto 861-1196, Japan; moris{at}saisyunsou1.hosp.go.jp

Statistics from Altmetric.com

Renal involvement is frequently present in patients with rheumatoid arthritis (RA). Approximately 15–25% of patients with RA have renal insufficiency, defined as a glomerular filtration rate (GFR) <60 mL/min.1 Although concomitant use of methotrexate (MTX) has been proven to be more effective than administration of biological agents alone,2 MTX elimination is delayed in patients with renal insufficiency, which can increase the risk of adverse events.3 ,4 Therefore we often use MTX at reduced dosage for these patients in daily practice, which may result in inadequate responses.

The ACTRA-RI (Actemra for RA patients with renal insufficiency) study was designed to evaluate the efficacy and safety of tocilizumab (TCZ) therapy in the real-life registry of patients with RA and renal insufficiency. For this study, we registered all patients with RA who had begun TCZ therapy in participating hospitals as of January 2014 (total 405 patients with RA: 102 with renal insufficiency and 303 without). An estimated GFR (eGFR) was first calculated using an equation that had been …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.